Trusted Resource for Clinical Trials, Protocols & Progress
Rare disease clinical trials often face a major hurdle—patient scarcity. With fewer than 200,000 individuals typically affected by a rare condition, the eligible participant pool is inherently limited. In ultra-rare diseases, populations can shrink to fewer than 100 individuals worldwide, making conventional recruitment strategies inadequate.
Click to read the full article.
For rare diseases, traditional recruitment methods often fall short due to small, dispersed patient populations and diagnostic delays. Patient registries help bridge this gap by offering centralized databases of diagnosed or at-risk individuals, enabling sponsors and investigators to identify, screen, and engage patients more efficiently.
Click to read the full article.
Recruiting for rare disease trials is uniquely challenging due to the dispersed, limited population and complex diagnostic pathways. Patient advocacy groups (PAGs) have emerged as essential stakeholders in bridging the gap between research teams and patients. These organizations often maintain direct relationships with affected families, facilitate disease awareness, and provide a trusted platform for trial communication.
Click to read the full article.
Recruiting patients with rare diseases into clinical trials is exceptionally challenging due to their small, geographically dispersed populations. Traditional methods—mass advertising, physician referrals, or clinic-based outreach—rarely yield results in this context. Here, patient registries emerge as a powerful solution, enabling the identification of trial-eligible individuals from curated, disease-specific databases.
Click to read the full article.
Given the inherently small and geographically dispersed populations affected by rare diseases, clinical trial sponsors often need to recruit participants from multiple countries to achieve statistically relevant sample sizes. Unlike common diseases, where thousands of patients might be available within one region, a rare disease trial may require outreach across continents to enroll even 50 eligible participants.
Click to read the full article.
Rare disease clinical trials often face the dual challenge of low patient numbers and wide geographic dispersion. Traditional site-based models are typically unviable due to the logistical burden placed on patients and families, many of whom may live far from major research centers. This is where decentralized clinical trial (DCT) models come into play.
Click to read the full article.
Rare disease trials often struggle with recruitment due to small, geographically dispersed patient populations. Traditional recruitment channels—clinic referrals, physician networks, or registry outreach—may not be sufficient to meet enrollment goals. Social media has emerged as a powerful tool to bridge this gap, enabling researchers to reach global patient communities with speed, precision, and personalization.
Click to read the full article.
In rare disease clinical trials, eligible patients are often scattered across large geographic regions, frequently far from study sites. The need to travel long distances—sometimes across states or international borders—can deter participation, particularly for families already managing the emotional and financial stress of a rare diagnosis.
Click to read the full article.
Patient retention is a cornerstone of clinical trial success—especially in rare disease studies where the patient pool is extremely limited. While much attention is given to recruitment, retaining patients over the course of long, complex, and sometimes invasive studies is equally critical. High dropout rates can compromise data integrity, extend trial timelines, and increase costs significantly.
Click to read the full article.
Ultra-rare diseases—typically defined as conditions affecting fewer than 1 in 50,000 individuals—present exceptional challenges in clinical research. In some cases, fewer than 100 known patients exist worldwide. These micro-populations are often spread across different countries, cultures, and languages, further complicating recruitment efforts.
Click to read the full article.
